Novo’s Wegovy Back On Track In Q4 But Broader Supply Issues Remain
Q4 Sales Edge Past Consensus
Now that US supply of the Danish firm’s blockbuster obesity product is back in full swing, Novo is focusing on diversifying its pipeline to reduce dependence on its GLP-1 franchise.
You may also be interested in...
Lilly Offloads Baqsimi To Amphastar While Investing In Mounjaro Head-To-Head Trial
Although Lilly said the glucagon spray’s relatively low sales were not a factor, the pharma may be prioritizing investment on its newer diabetes and weight-loss drug Mounjaro.
Novo Preempts Earnings Reveal With Preview Of Wegovy-Driven Growth
Novo Nordisk said sales increased 25% in the first quarter, driven by US demand for GLP-1 agonist Wegovy for obesity, and increased its 2023 sales growth guidance from a range of 13%-19% to 24%-30%.
Wegovy CVOT Data Could Pave The Way For Broad Reimbursement, CEO Says
Novo Nordisk CEO Lars Jørgensen discussed the supply and market access position of its rising obesity drug, Wegovy, during the CNBC Health Returns conference.